<DOC>
	<DOC>NCT00557713</DOC>
	<brief_summary>The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine+radiotherapy), followed by surgery.</brief_summary>
	<brief_title>XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written informed consent from patients who are able to understand the study request Histologically confirmed diagnosis of locally advanced rectal adenocarcinoma; ≤12 cm from the anal margin; T3, operable T4 or TxN+ Karnofsky PS Index ≥ 70% Life expectancy &gt; 6 months Adequate bone marrow, liver and renal function: ANC ≥ 1.5 x 10e9/l; Platelets ≥ 100 x 10e9/l; Hb ≥ 9g/dl; INR ≤ 1.5; Bilirubin ≤ 1.5 x ULN; ALT and/or AST ≤ 2.5 x ULN or ≤ 5 x ULN (in case of hepatic metastasis); Alkaline phosphatase ≤ 2.5 x ULN or ≤ 5 x ULN (in case of hepatic metastasis) or ≤ 10 x ULN (in case of bone metastasis); Creatinine clearance (CockcroftGault) ≥ 30 ml/min or seric creatinine ≤ 1.5 x ULN Distant metastases; previous neoplasm during last 5 years or previous infiltrating neoplasm; previous treatment with radiotherapy or study drugs; recruited for other clinical trial in 4 weeks before study entry Surgery, open biopsy or traumatic injury in 4 weeks before study entry; fineneedle aspiration in 7 days before study entry; major surgery planned during study Previous heart disease or uncontrolled hypertension, previous hemorrhagic diathesis or coagulopathy; fulldose oral or parenteral anticoagulant or thrombolytic agent (lowdose warfarin is allowed, INR ≤ 1.5); chronic use of highdose aspirin (&lt;325mg/day) or nonsteroidal antiinflammatory treatment No integrity of the upper gastrointestinal tract, malabsorption syndrome or unable to take oral drugs Pregnant or lactating patients; SNC disease; allogeneic transplant with immunosuppressive drugs; bone fracture not healed, wound or severe ulcers; uncontrolled intercurrent severe infections; previous relatedfluoropyrimide SAEs or DPD deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>